Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
CAR-T cells targeting CD19 and CD22
DRUG
3 trials
Sponsors
Zhejiang University
, University Hospital Tuebingen
Conditions
Acute Lymphoblastic Leukemia, Pediatric
B-Cell Acute Lymphoblastic Leukemia, Adult
CLL
Lymphoma
Phase 1
Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL
NCT04740203
Zhejiang University
B-Cell Acute Lymphoblastic Leukemia, Adult
Start: 2021-01-31
End: 2025-01-31
Target: 50
Updated: 2021-02-05
A Phase I Dose Finding Study of MB-CART2219.1
Recruiting
NCT07108868
University Hospital Tuebingen
Acute Lymphoblastic Leukemia, Pediatric, CLL, Lymphoma
Start: 2025-06-23
End: 2027-06-30
Target: 36
Updated: 2025-08-07
Phase 2
Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL
Completed
NCT04788472
Zhejiang University
B-Cell Acute Lymphoblastic Leukemia, Adult
Start: 2021-03-05
End: 2024-08-31
Updated: 2024-10-17
Related Papers
Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
JAMA Oncology
2025-04-17
12 citations